Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest Brahn

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|May 12, 2009
Angiogenesis inhibitors for the treatment of chronic autoimmune inflammatory arthritisNathan Schoettler, Ernest Brahn
Expert Opinion on Investigational Drugs|July 12, 2008
Inflammatory lipids as a target for therapy in the rheumatic diseasesMaureen McMahon, Ernest Brahn
Clinical Rheumatology|October 8, 2016
Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisionsAmit Lakhanpal, Ernest Brahn
European Journal of Rheumatology|May 26, 2020
A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeuticsAmit Lakhanpal, Ernest Brahn
Seminars in Arthritis and Rheumatism|November 3, 2009
Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomyAmy Wasserman, Ernest Brahn
European Journal of Rheumatology|January 9, 2018
Microscopic polyangiitis with dermatomyositisErin M Bauer, Ernest Brahn
Nature Clinical Practice. Rheumatology|August 1, 2007
Angiogenesis inhibition as a therapeutic approach for inflammatory synovitisDahlia Lainer-Carr, Ernest Brahn
The Journal of Rheumatology|May 5, 2004
Is erythrocyte sedimentation rate the preferable measure of the acute phase response in rheumatoid arthritis?Harold E Paulus, Ernest Brahn
Autoimmunity|May 1, 2010
Rheumatoid arthritis therapy: advances from bench to bedsideSoo-In Choi, Ernest Brahn
Clinical Immunology (Orlando, Fla.)|April 6, 2018
Cytokine targeting in rheumatoid arthritisViet L Bui, Ernest Brahn
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Current Opinion in Investigational Drugs (London, England : 2000)|May 12, 2009
Angiogenesis inhibitors for the treatment of chronic autoimmune inflammatory arthritisNathan Schoettler, Ernest Brahn
Expert Opinion on Investigational Drugs|July 12, 2008
Inflammatory lipids as a target for therapy in the rheumatic diseasesMaureen McMahon, Ernest Brahn
Clinical Rheumatology|October 8, 2016
Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisionsAmit Lakhanpal, Ernest Brahn
European Journal of Rheumatology|May 26, 2020
A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeuticsAmit Lakhanpal, Ernest Brahn
Seminars in Arthritis and Rheumatism|November 3, 2009
Systemic sclerosis: bilateral improvement of Raynaud's phenomenon with unilateral digital sympathectomyAmy Wasserman, Ernest Brahn
European Journal of Rheumatology|January 9, 2018
Microscopic polyangiitis with dermatomyositisErin M Bauer, Ernest Brahn
Nature Clinical Practice. Rheumatology|August 1, 2007
Angiogenesis inhibition as a therapeutic approach for inflammatory synovitisDahlia Lainer-Carr, Ernest Brahn
The Journal of Rheumatology|May 5, 2004
Is erythrocyte sedimentation rate the preferable measure of the acute phase response in rheumatoid arthritis?Harold E Paulus, Ernest Brahn
Autoimmunity|May 1, 2010
Rheumatoid arthritis therapy: advances from bench to bedsideSoo-In Choi, Ernest Brahn
Clinical Immunology (Orlando, Fla.)|April 6, 2018
Cytokine targeting in rheumatoid arthritisViet L Bui, Ernest Brahn
Pageof 3